18 Feb 2026
// PRESS RELEASE
26 Jan 2026
// PRESS RELEASE
23 Jan 2026
// PRESS RELEASE
Latest Content by PharmaCompass
KEY PRODUCTSBioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
About
Industry Trade Show
Attending
16-18 May, 2026
Industry Trade Show
Booth #4A33
06-08 October, 2026
Industry Trade Show
Not Confirmed
01-02 April, 2026
CONTACT DETAILS



Events
Webinars & Exhibitions
Industry Trade Show
Attending
16-18 May, 2026
Industry Trade Show
Booth #4A33
06-08 October, 2026
Industry Trade Show
Not Confirmed
01-02 April, 2026
CORPORATE CONTENT #SupplierSpotlight

18 Feb 2026
// PRESS RELEASE
https://www.bioiberica.com/en/inspiring-insights/received-frost-sullivans-2025-european-new-product-innovation-award-clinically

26 Jan 2026
// PRESS RELEASE
https://www.bioiberica.com/en/inspiring-insights/cereals-europe-global-demand-environmental-restrictions-technologies-sustain

23 Jan 2026
// PRESS RELEASE
https://www.bioiberica.com/en/inspiring-insights/sergi-segarra-science-main-guarantee-safety-efficacy

20 Jan 2026
// PRESS RELEASE
https://www.bioiberica.com/en/inspiring-insights/bioiberica-partners-lactalis-launch-industry-first-functional-milk-beverage

15 Dec 2025
// PRESS RELEASE
https://www.bioiberica.com/en/inspiring-insights/study-confirms-bioactive-peptides-palbior-hydrolyzed-protein-animal-nutrition

11 Dec 2025
// PRESS RELEASE
https://www.bioiberica.com/en/inspiring-insights/presented-terra-sorb-symbioticr-biostimulant-world-congress-barcelona-drive
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-05-09
Pay. Date : 2013-04-26
DMF Number : 17838
Submission : 2004-11-03
Status : Active
Type : II
Registration Number : 302MF10020
Registrant's Address : C/Antic Cami de Tordera, 109-119, Palafolls, 08389 Barcelona, Spain
Initial Date of Registration : 2020-01-31
Latest Date of Registration :
NDC Package Code : 53484-001
Start Marketing Date : 2009-08-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Certificate Number : CEP 2023-243 - Rev 02
Issue Date : 2024-12-18
Type : Chemical and TSE
Substance Number : 2064
Status : Valid
Registrant Name : Optus Pharmaceutical Co., Ltd.
Registration Date : 2014-05-23
Registration Number : 20131119-173-I-277-03(5)
Manufacturer Name : Bioiberica, SA
Manufacturer Address : Ctra. Nacional II, Km 680.6, 08389, Palafolls, Barcelona, Spain.
Certificate Number : R1-CEP 2007-197 - Rev 02
Issue Date : 2019-03-27
Type : TSE
Substance Number : 2064
Status : Valid
Registrant Name : Samjin Pharmaceutical Co., Ltd.
Registration Date : 2014-03-10
Registration Number : 20131119-173-I-277-03(4)
Manufacturer Name : Bioiberica SAU
Manufacturer Address : c/ Antic Camí de Tordera, 109-119 08389 Palafolls Barcelona
Certificate Number : CEP 2001-063 - Rev 07
Issue Date : 2025-12-11
Type : TSE
Substance Number : 2064
Status : Valid
Registrant Name : Sanil Pharma Co., Ltd.
Registration Date : 2015-05-29
Registration Number : 20131119-173-I-277-03(6)
Manufacturer Name : Bioiberica SA
Manufacturer Address : Ctra. Nacional II, Km 680.6, 08389, Palafolls, Barcelona, Spain.
Certificate Number : CEP 2024-106 - Rev 01
Issue Date : 2025-04-10
Type : Chemical
Substance Number : 2064
Status : Valid
Registrant Name : Samchundang Pharmaceutical Co., Ltd.
Registration Date : 2014-02-07
Registration Number : 20131119-173-I-277-03(3)
Manufacturer Name : Bioiberica, SAU
Manufacturer Address : C/ Antic Camí de Tordera, 109-119 08389 Palafolls (Barcelona), Spain
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26680
Submission : 2013-01-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31738
Submission : 2017-05-17
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2013-05-09
Pay. Date : 2013-04-26
DMF Number : 17838
Submission : 2004-11-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31738
Submission : 2017-05-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26680
Submission : 2013-01-07
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
In a new partnership, Collagen Type II dietary supplement will target joint pain, aiming to improve overall joint health.
Lead Product(s): Collagen Type II
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Dietary Supplement
Sponsor: Stauber
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 11, 2025
Lead Product(s) : Collagen Type II
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Stauber
Deal Size : Undisclosed
Deal Type : Partnership
Bioiberica Partners with STAUBER to Expand Distribution of Branded Ingredients in US
Details : In a new partnership, Collagen Type II dietary supplement will target joint pain, aiming to improve overall joint health.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
February 11, 2025
Details:
HA Matrix is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Skin Aging.
Lead Product(s): HA Matrix
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2023
Lead Product(s) : HA Matrix
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®
Details : HA Matrix is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Skin Aging.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
April 14, 2023
Details:
Aim is to develop innovative multifunctional biomaterials to heal wounds using affordable EU-based manufacturing technologies.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioiberica Joins a European Project to Develop Treatments for Complex Wounds
Details : Aim is to develop innovative multifunctional biomaterials to heal wounds using affordable EU-based manufacturing technologies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 18, 2023
Details:
New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.
Lead Product(s): Hyaluronic Acid,Collagen,Dermatan Sulfate
Therapeutic Area: Dermatology Brand Name: Dermial
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 25, 2022
Lead Product(s) : Hyaluronic Acid,Collagen,Dermatan Sulfate
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
New Study Reveals Bioiberica's Dermial® Delivers Superior Benefits for Skin Health
Details : New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.
Product Name : Dermial
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2022
Details:
Native Type Ii Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Arthralgia.
Lead Product(s): Native Type Ii Collagen
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 16, 2022
Lead Product(s) : Native Type Ii Collagen
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NAtive Collagen Type II In Healthy VoluntEers With Joint Discomfort
Details : Native Type Ii Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Arthralgia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 16, 2022
Details:
By partnering with Bioiberica, ByHealth aims to capitalise on the untapped potential of new product development with native type II collagen and respond to the growing number of consumers looking to support their mobility with effective, convenient products across the country.
Lead Product(s): Collavant n2
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Protein
Sponsor: ByHealth
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 11, 2022
Lead Product(s) : Collavant n2
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : ByHealth
Deal Size : Undisclosed
Deal Type : Partnership
New Partnership With ByHealth in China
Details : By partnering with Bioiberica, ByHealth aims to capitalise on the untapped potential of new product development with native type II collagen and respond to the growing number of consumers looking to support their mobility with effective, convenient produ...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
March 11, 2022
Details:
Bioiberica’s native (undenatured) type II collagen, Collavant® n2 (previously b2-Cool®) and the addition of Tendaxion® - a new brand for its tendon health ingredient.
Lead Product(s): Chondroitin Sulfate Sodium
Therapeutic Area: Musculoskeletal Brand Name: CSbioactive
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 05, 2021
Lead Product(s) : Chondroitin Sulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioiberica Rebrands Its Range of Nutraceutical Ingredients for Healthcare
Details : Bioiberica’s native (undenatured) type II collagen, Collavant® n2 (previously b2-Cool®) and the addition of Tendaxion® - a new brand for its tendon health ingredient.
Product Name : CSbioactive
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 05, 2021
Details:
Apsen’s Motilex HA combines two leading ingredients, b-2Cool native type II collagen and Mobilee, patented ingredient that synergistically combines a high concentration of hyaluronic acid with polysaccharides and collagen, to effectively maintain joint function.
Lead Product(s): Hyaluronic Acid,Type II Collagen
Therapeutic Area: Musculoskeletal Brand Name: Motilex HA
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Apsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 26, 2021
Lead Product(s) : Hyaluronic Acid,Type II Collagen
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Apsen
Deal Size : Undisclosed
Deal Type : Partnership
Bioiberica and Apsen Reinforce Partnership with New Holistic Mobility Product–Motilex HA
Details : Apsen’s Motilex HA combines two leading ingredients, b-2Cool native type II collagen and Mobilee, patented ingredient that synergistically combines a high concentration of hyaluronic acid with polysaccharides and collagen, to effectively maintain joint...
Product Name : Motilex HA
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 26, 2021
Details:
B-2Cool (Bioiberica’s native type II collagen) is an innovative ingredient, has been shown in four scientific studies to help maintain good joint health at a very low daily dose.
Lead Product(s): Undenatured Type II Collagen,Harpagophytum Procumbens Extract,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 15, 2020
Lead Product(s) : Undenatured Type II Collagen,Harpagophytum Procumbens Extract,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Laboratorios Ordesa Incorporates B-2cool®, Bioiberica’s Native Type II Collagen, in Its New Col...
Details : B-2Cool (Bioiberica’s native type II collagen) is an innovative ingredient, has been shown in four scientific studies to help maintain good joint health at a very low daily dose.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 15, 2020
Details:
Nestlé Health Science is incorporating Bioiberica’s patented ingredient, Mobilee®, into its MERITENE® Mobilis® joint-health drink mix.
Lead Product(s): Hyaluronic Acid,Type II Collagen,Polysaccharides
Therapeutic Area: Musculoskeletal Brand Name: Meritene Mobilis
Study Phase: UndisclosedProduct Type: Miscellaneous
Recipient: Nestle Health Sciences SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 16, 2020
Lead Product(s) : Hyaluronic Acid,Type II Collagen,Polysaccharides
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Recipient : Nestle Health Sciences SA
Deal Size : Undisclosed
Deal Type : Partnership
Nestlé Health Science Partners with Bioiberica to Deliver Innovative Nutrition in Joint Health an...
Details : Nestlé Health Science is incorporating Bioiberica’s patented ingredient, Mobilee®, into its MERITENE® Mobilis® joint-health drink mix.
Product Name : Meritene Mobilis
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients
Inspections and registrations
Country : Spain
City/Region : Palafolls, Barcelona
Audit Date : 2024-05-09
Audit Type : On-Site
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Bioiberica SA is a supplier offers 11 products (APIs, Excipients or Intermediates).
Find a price of Heparin Sodium bulk with DMF, JDMF offered by Bioiberica SA
Find a price of Chondroitin Sulfate Sodium bulk with CEP offered by Bioiberica SA
Find a price of Heparin Sodium bulk with DMF offered by Bioiberica SA
Find a price of Chondroitin Sulfate Sodium bulk offered by Bioiberica SA
Find a price of Glucosamine bulk offered by Bioiberica SA
Find a price of Glucosamine Hydrochloride bulk offered by Bioiberica SA
Find a price of Glucosamine Sulfate Potassium Chloride bulk offered by Bioiberica SA
Find a price of Glucosamine Sulfate Sodium Chloride bulk offered by Bioiberica SA
Find a price of Heparin Lithium bulk offered by Bioiberica SA
Find a price of Liothyronine Sodium bulk offered by Bioiberica SA
Find a price of Thyroid bulk offered by Bioiberica SA
Bioiberica SA



